PRINCETON, N.J., Oct. 9 BioWa, Inc. announced today thatit has entered into a license agreement with CSL Limited, providing CSL withaccess to BioWa's POTELLIGENT(R) Technology platform for the research anddevelopment of antibody therapeutics with enhanced antibody-dependent cellularcytotoxicity (ADCC).
"We are very pleased to have this opportunity to work with CSL, our firstAustralian partner," said Dr. Masamichi Koike, President and CEO of BioWa."We believe that CSL's strength in biologics and significant presence inAustralia and many other countries will help the technology to reach broaderfields and territories."
Under the license agreement, CSL obtains non-exclusive rights to usePOTELLIGENT(R) Technology platform to research, develop, manufacture, andcommercialize ADCC-enhanced antibodies for an undisclosed number of targets.In return, BioWa will receive upfront technology access fee, and may receivedevelopment milestone payments and royalties on products developed by CSL.Additional terms were not disclosed.
About POTELLIGENT(R) Technology
POTELLIGENT(R) Technology improves potency and efficacy of antibodytherapeutics, by enhancing ADCC, one of the major mechanisms of action forantibody therapeutics. POTELLIGENT(R) Technology involves the reduction ofthe amount of fucose in the carbohydrate structure of an antibody using aproprietary fucosyltransferase-knockout CHO cell line as a production cell.Research shows that POTELLIGENT(R) Technology dramatically enhances ADCCactivity of an antibody in vitro, and significantly increases potency andefficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies arebeing investigated in human clinical trials.
About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan'sleading pharmaceutical and largest biotech company, and is the exclusiveworldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platformconsists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating asuperior antibody molecule with enhanced ADCC and CDC activities. BioWa isoffering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under alicense to maximize the value of these technologies. Together with KyowaHakko Kirin, BioWa is focused on development of ADCC/CDC enhanced monoclonalantibody-based therapeutics to fight cancer and other life-threatening anddebilitating diseases. For more information about BioWa, visit its web siteat www.biowa.com.
POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks ofKyowa Hakko Kirin Co., Ltd. All rights are reserved.
SOURCE BioWa, Inc.